Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Cutaneous Lupus Erythematosus
Recruiting0 awardsPhase 2
Bronx, New York
This trial is testing a new medication called deucravacitinib to help people with certain types of lupus that aren't well managed by current treatments. The medication works by calming the immune system to reduce skin damage.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service